20/20 BIOLABS, INC. Accounts Receivable, Credit Loss Expense (Reversal)
20/20 BIOLABS, INC. (AIDX) reported Accounts Receivable, Credit Loss Expense (Reversal) of $59.87 thousand for the 12-month period ending 2025-12-31, per its POS AM filed 2026-04-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForDoubtfulAccounts · last filed 2026-04-06
| Period end | Accounts Receivable, Credit Loss Expense (Reversal) 12 month |
|---|---|
| 2025-12-31 | $59.87K POS AM · filed 2026-04-06 |
| 2024-12-31 | $49.65K POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |